Breaking the cycle: A series of N‐(2‐arylindol‐7‐yl)benzenesulfonamidederivatives were prepared. Among them, compound 2 showed promising antiproliferative activity against hormone‐resistant prostate cancer PC‐3 cells, induced G2/M‐phase arrest, and induced apoptosis through a caspase‐dependent pathway.